A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. by Svensson, T, Chowdhury, O, Garelius, H, Lorenz, F, Saft, L, Jacobsen, SE, Hellström-Lindberg, E, Cherif, H

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. by Jädersten, M, Saft, L, Pellagatti, A, Göhring, G, Wainscoat, J, Boultwood, J, Porwit, A, Schlegelberger, B, Hellström-Lindberg, E

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment by Scharenberg, C, Giai, V, Pellagatti, A, Saft, L, Karlsson, G, Jansson, M, Forsblom, L, Jadersten, M, Karlsson, S, Boultwood, J, Hellstrom-Lindberg, E

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. by Della Porta, MG, Picone, C, Pascutto, C, Malcovati, L, Tamura, H, Handa, H, Czader, M, Freeman, S, Vyas, P, Porwit, A, Saft, L, Westers, T, Alhan, C, Cali, C, van de Loosdrecht, A, Ogata, K

Progression in patients with low- and intermediate1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. by Scharenberg, C, Giai, V, Pellagatti, A, Saft, L, Dimitriou, M, Jansson, M, Jädersten, M, Grandien, A, Douagi, I, Neuberg, D, LeBlanc, K, Boultwood, J, Karimi, M, Jacobsen, S, Woll, P, Hellström-Lindberg, E

MULTICENTRE VALIDATION OF A REPRODUCIBLE FLOW CYTOMETRIC SCORE FOR THE DIAGNOSIS OF LOWRISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A EUROPEAN LeukemiaNET STUDY by Picone, C, Tenore, A, Vanelli, L, Malcovati, L, Pascutto, C, Ogata, K, Tamura, H, Handa, H, Czader, M, Freeman, S, Vyas, P, Porwit, A, Saft, L, Westers, T, Alhan, C, Cali, C, van de Loosdrecht, A, Cazzola, M, Della Porta, MG